Drugs / Sinovac PCV24 formulation 1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06550830 | Sep 2024 → Jun 2025 | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06474377 | Jun → Aug 2024 | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sinovac PCV24 formulation 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06550830 ↗ |
| Known as | PCV24 | “A Phase Ia clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2-17 years.” NCT06550830 ↗ |
| Modality | Vaccine | “24-valent pneumococcal conjugate vaccine (PCV24)” NCT06474377 ↗ |
| Route | Intramuscular | “Route of administration is intramuscular injection at deltoid muscle of upper arm.” NCT06474377 ↗ |